SP Stenning

2.9k total citations
41 papers, 1.3k citations indexed

About

SP Stenning is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Genetics. According to data from OpenAlex, SP Stenning has authored 41 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 17 papers in Surgery and 10 papers in Genetics. Recurrent topics in SP Stenning's work include Testicular diseases and treatments (13 papers), Glioma Diagnosis and Treatment (9 papers) and Sarcoma Diagnosis and Treatment (7 papers). SP Stenning is often cited by papers focused on Testicular diseases and treatments (13 papers), Glioma Diagnosis and Treatment (9 papers) and Sarcoma Diagnosis and Treatment (7 papers). SP Stenning collaborates with scholars based in United Kingdom, Denmark and United States. SP Stenning's co-authors include NM Bleehen, Michel Seymour, Graham M. Mead, R.T.D. Oliver, David Cunningham, W H Allum, Simon Weeden, K Birbeck, Philip Quirke and Clare Walker and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

SP Stenning

40 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
SP Stenning United Kingdom 16 521 462 424 386 194 41 1.3k
E. Quintana France 19 614 1.2× 506 1.1× 180 0.4× 335 0.9× 225 1.2× 29 1.3k
Pramod Kumar Julka India 22 478 0.9× 411 0.9× 382 0.9× 326 0.8× 172 0.9× 124 1.6k
Federico L. Ampil United States 20 447 0.9× 372 0.8× 180 0.4× 447 1.2× 177 0.9× 115 1.1k
Naoto Shikama Japan 22 504 1.0× 626 1.4× 283 0.7× 479 1.2× 372 1.9× 156 1.7k
Giampaolo Biti Italy 22 604 1.2× 237 0.5× 177 0.4× 449 1.2× 278 1.4× 88 1.4k
Silvia Scoccianti Italy 20 680 1.3× 236 0.5× 541 1.3× 356 0.9× 170 0.9× 75 1.6k
J.H. Meerwaldt Netherlands 21 885 1.7× 422 0.9× 331 0.8× 672 1.7× 620 3.2× 41 1.9k
Lynn G. Ries United States 12 359 0.7× 222 0.5× 225 0.5× 791 2.0× 307 1.6× 13 1.8k
Sarah Taylor United States 17 681 1.3× 316 0.7× 234 0.6× 998 2.6× 211 1.1× 38 1.9k
Christine Haie‐Méder France 22 703 1.3× 811 1.8× 183 0.4× 274 0.7× 103 0.5× 63 1.7k

Countries citing papers authored by SP Stenning

Since Specialization
Citations

This map shows the geographic impact of SP Stenning's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by SP Stenning with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites SP Stenning more than expected).

Fields of papers citing papers by SP Stenning

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by SP Stenning. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by SP Stenning. The network helps show where SP Stenning may publish in the future.

Co-authorship network of co-authors of SP Stenning

This figure shows the co-authorship network connecting the top 25 collaborators of SP Stenning. A scholar is included among the top collaborators of SP Stenning based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with SP Stenning. SP Stenning is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fosså, S. D., et al.. (2010). Risk of second cancers among a cohort of 2,703 long-term survivors of testicular seminoma treated with radiotherapy.. Journal of Clinical Oncology. 28(15_suppl). 4538–4538. 5 indexed citations
2.
Allum, W H, et al.. (2008). Long term results of the MRC OEO2 randomized trial of surgery with or without preoperative chemotherapy in resectable esophageal cancer. UCL Discovery (University College London). 11 indexed citations
3.
Brada, M., et al.. (2008). A RANDOMISED TRIAL OF PROCARBAZINE, CCNU AND VINCRISTINE (PCV) VS TEMOZOLOMIDE (5-DAY OR 21-DAY SCHEDULE) FOR RECURRENT HIGH GRADE GLIOMA (MRC BR12, ISRCTN83176944). UCL Discovery (University College London). 7 indexed citations
4.
Cunningham, David, et al.. (2005). Perioperative chemotherapy in operable gastric and lower oesophageal cancer: Final results of a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971). UCL Discovery (University College London). 12 indexed citations
5.
Hancock, Bruno C., John Radford, M.H. Cullen, et al.. (2004). Randomised controlled trial of ABVD vs. two multi-drug regimens (MDRs) for advanced Hodgkin's lymphoma (HL): Initial results of UKLG LY09 (ISRCTN97144519).. British Journal of Cancer. 91. 1 indexed citations
6.
Oliver, R.T.D., M Mason, Hans von der Maase, et al.. (2004). A randomised trial of carboplatin versus radiotherapy for stage I seminoma of the testis, following orchidectomy: MRC TE19/EORTC 30982. UCL Discovery (University College London). 1 indexed citations
7.
Oliver, R.T.D., M. Mason, Hélène Massé, et al.. (2004). A randomised comparison of single agent carboplatin with radiotherapy in the adjuvant treatment of stage I seminoma of the testis, following orchidectomy: MRC TE19/EORTC 30982. Journal of Clinical Oncology. 22(14_suppl). 4517–4517. 6 indexed citations
8.
Radford, John, M.H. Cullen, Matthew R. Sydes, et al.. (2003). Randomised comparison of ABVD with two multi-drug regimens (MDRs) in the treatment of advanced Hodgkin lymphoma (HL): Initial results of the UKLG LY09 study (ISRCTN 97144519).. Blood. 102(11). 2 indexed citations
9.
Brada, M., et al.. (2001). Randomized trial of porcarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: A medical research council trial. Journal of Clinical Oncology. 16 indexed citations
10.
Seymour, Michel, et al.. (1999). Molecular markers and the prediction of prognosis and response to therapy in colon cancer. UCL Discovery (University College London). 1 indexed citations
11.
Stenning, SP, et al.. (1998). Residual masses post-chemotherapy for germ cell tumour: content, clinical features and prognosis. UCL Discovery (University College London). 1 indexed citations
12.
Fosså, S.D., Stuart Kaye, S. J. Harland, et al.. (1998). Adjuvant bleomycin, vincristine and cisplatin (BOP) for high risk clinical stage I (HRCS 1) non-seminomatous germ cell tumours (NSGCT) - a Medical Research Council (MRC) pilot study.. UCL Discovery (University College London). 12 indexed citations
13.
Mead, G.M., NM Bleehen, A. Gregor, et al.. (1998). Medical Research Council (MRC) randomised trial of adjuvant chemotherapy in primary CNS lymphoma (PCL)- BR06.. UCL Discovery (University College London). 1 indexed citations
14.
Stenning, SP, et al.. (1997). Value of CA15.3 in marking relapse in breast cancer. UCL Discovery (University College London). 1 indexed citations
15.
Ford, James M., et al.. (1997). A short fractionation radiotherapy treatment for poor prognosis patients with high grade glioma. Clinical Oncology. 9(1). 20–24. 34 indexed citations
16.
Fosså, S.D., et al.. (1996). Optimal field size in adjuvant radiotherapy (XRT) of stage I seminoma - a randomised trial. UCL Discovery (University College London). 8 indexed citations
18.
Stenning, SP, et al.. (1992). Short course adjuvant chemotherapy in high risk stage I non-seminomatous germ cell tumours of the testis - preliminary report of an MRC study. UCL Discovery (University College London). 4 indexed citations
19.
Bleehen, NM & SP Stenning. (1991). A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. British Journal of Cancer. 64(4). 769–774. 315 indexed citations
20.
Stenning, SP, et al.. (1990). Prognostic factors for survival in advanced non-seminomatous germ cell tumours: A study by the Medical Research Council Testicular Tumours Working Party. UCL Discovery (University College London). 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026